Charles Schwab Investment Management Inc. Boosts Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Charles Schwab Investment Management Inc. boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 9.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 297,433 shares of the company’s stock after acquiring an additional 25,739 shares during the period. Charles Schwab Investment Management Inc. owned 0.89% of TransMedics Group worth $18,545,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Hager Investment Management Services LLC purchased a new position in shares of TransMedics Group in the 4th quarter worth $33,000. Sachetta LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth about $40,000. Quarry LP lifted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI lifted its holdings in shares of TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the last quarter. Finally, Arcadia Investment Management Corp MI bought a new stake in shares of TransMedics Group in the 4th quarter worth about $72,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Trading Up 1.9 %

NASDAQ TMDX opened at $70.33 on Thursday. The company’s 50-day simple moving average is $68.19 and its two-hundred day simple moving average is $91.91. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 74.82 and a beta of 2.12.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TMDX shares. Piper Sandler lowered their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Oppenheimer reiterated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Robert W. Baird decreased their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.